Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28744759 | 1.00 | KMT2A (0.34) | KMT2AMEN1GAALMNACYP2D6 | |
| SCHEMBL27504700 | 0.83 | TDP1 (0.41) | KMT2AMEN1GAACYP2D6NOS1 | |
| SCHEMBL28655193 | 0.79 | CTSK (0.38) | KMT2AMEN1GAACYP2D6 | |
| SCHEMBL4274595 | 0.79 | CTSK (0.38) | KMT2AMEN1GAACYP2D6 | |
| SCHEMBL17280297 | 0.74 | CYP2D6 (0.36) | KMT2ALMNACYP2D6NOS1NOS3 | |
| SCHEMBL3431573 | 0.74 | PDE4A (0.37) | KMT2AMEN1GAALMNACYP2D6 | |
| SCHEMBL17280296 | 0.74 | CYP2D6 (0.36) | KMT2ALMNACYP2D6NOS1NOS3 | |
| SCHEMBL1260481 | 0.73 | KMT2A (0.31) | KMT2AMEN1GAALMNA | |
| SCHEMBL27416647 | 0.73 | MEN1 (0.36) | KMT2AMEN1GAACYP2D6NOS1 | |
| SCHEMBL27537985 | 0.73 | SMN1; SMN2 (0.36) | KMT2AMEN1GAALMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021057014-A1 | KLUYVEROMYCES MARXIANUS ALDO-KETO REDUCTASE KMAKR MUTANT AND APPLICATION THEREOF | 浙江工业大学 | 2021-04-01 | — | — | WO | claimed |
| CN-113621589-A | Aldehyde ketone reductase KmAKR mutant, engineering bacteria and application thereof | 浙江工业大学 | 2021-11-09 | — | — | CN | disclosed |
| WO-2021057014-A1 | KLUYVEROMYCES MARXIANUS ALDO-KETO REDUCTASE KMAKR MUTANT AND APPLICATION THEREOF | 浙江工业大学 | 2021-04-01 | — | — | WO | disclosed |
| CN-110577940-A | Kluyveromyces marxianus aldehyde ketone reductase KmAKR mutant and application thereof | 浙江工业大学 | 2019-12-17 | — | — | CN | disclosed |
| CN-104844457-B | Preparation method for tert-butyl-(3R,5S)-6-chlorodihydroxyhexanoate | 爱斯特（成都）生物制药有限公司 | 2017-04-12 | — | — | CN | disclosed |
| CN-104844457-B | Preparation method for tert-butyl-(3R,5S)-6-chlorodihydroxyhexanoate | 爱斯特（成都）生物制药有限公司 | 2017-04-12 | — | — | CN | disclosed |
| CN-104844457-A | Preparation method for tert-butyl-(3R,5S)-6-chlorodihydroxyhexanoate | ASTATECH CHENGDU PHARM CO LTD | 2015-08-19 | — | — | CN | disclosed |
| CN-104844457-A | Preparation method for tert-butyl-(3R,5S)-6-chlorodihydroxyhexanoate | ASTATECH CHENGDU PHARM CO LTD | 2015-08-19 | — | — | CN | disclosed |
| US-8617864-B2 | Polynucleotides encoding ketoreductases for producing stereoisomerically pure statins and synthetic intermediates therefor | CODEXIS, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130040364-A1 | POLYNUCLEOTIDES ENCODING KETOREDUCTASES FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR | CODEXIS, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20080248539-A1 | COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR | CODEXIS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080248539-A1 | COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR | COASY, FAR1, HMGCR | KMT2A 2252/4885MEN1 3582/4885GAA 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.